NRX Pharmaceuticals (NRXP) said Friday data from a mid-stage trial showed that the BriLife COVID19 vaccine may be able to protect against the delta variant of SARS-CoV-2, the virus that causes COVID-19.
In the phase 2 study, 10 out of the 11 samples taken from participants to be tested for antibodies were found to neutralize the delta variant. Data suggests that the vaccine may be capable of evolving to counter delta and other variants of concern, the company said.
The company expects to start a phase 2b/3 registration trial of the vaccine after a review of the phase 2 study results by the data safety monitoring board. It is developing BriLife under an exclusive license from the Israel Ministry of Defense.
Trade active:
Its Resting as after PreMarket Marathon makes NRXP Tired.
will take the Baton to Next Level which is 12 and take another break... lets cheer up
All the Very best for all who hold their breath with NRXP
will take the Baton to Next Level which is 12 and take another break... lets cheer up
All the Very best for all who hold their breath with NRXP